Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

2.0K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.0K
Adrenergic Agonists: Therapeutic Classification01:18

Adrenergic Agonists: Therapeutic Classification

1.7K
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
1.7K
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

1.8K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.8K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.0K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K
Therapeutic Index01:13

Therapeutic Index

6.9K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
6.9K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

4.2K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>Anaplasma phagocytophilum</i> subversion of host hepcidin-ferroportin iron nutritional immunity.

mBio·2026
Same author

Mechanisms of resistance to Tmprss6 antisense oligonucleotides in a mouse model of β-thalassemia.

Blood·2026
Same author

Disease-modifying effects of iron deficiency in mouse models of chronic renal failure.

Blood. Red cells & iron·2026
Same author

Evaluating the Risk of Hypophosphatemia with Ferric Carboxymaltose and the Recommended Approaches for Management: A Consensus Statement.

Journal of clinical medicine·2025
Same author

TNFα signaling restores steady-state hematopoiesis in a TNFαKO mouse model of anemia of inflammation.

Blood·2025
Same author

Transgenic augmentation of erythroferrone in mice ameliorates anemia in adenine-induced chronic kidney disease.

bioRxiv : the preprint server for biology·2024

Related Experiment Video

Updated: Feb 13, 2026

Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research
04:50

Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research

Published on: August 4, 2023

1.6K

Hepcidin agonists as therapeutic tools.

Carla Casu1, Elizabeta Nemeth2, Stefano Rivella1

  • 1Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA; and.

Blood
|March 11, 2018
PubMed
Summary
This summary is machine-generated.

Hepcidin agonists regulate iron levels and absorption, offering new treatments for iron disorders like hemochromatosis and beta-thalassemia. These compounds also show promise in preventing infections in patients with iron overload.

More Related Videos

The Synthesis of RGD-functionalized Hydrogels as a Tool for Therapeutic Applications
09:30

The Synthesis of RGD-functionalized Hydrogels as a Tool for Therapeutic Applications

Published on: October 7, 2016

12.0K
Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

19.8K

Related Experiment Videos

Last Updated: Feb 13, 2026

Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research
04:50

Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research

Published on: August 4, 2023

1.6K
The Synthesis of RGD-functionalized Hydrogels as a Tool for Therapeutic Applications
09:30

The Synthesis of RGD-functionalized Hydrogels as a Tool for Therapeutic Applications

Published on: October 7, 2016

12.0K
Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

19.8K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Hematology

Background:

  • Disrupted iron homeostasis underlies various diseases, including hemochromatosis, beta-thalassemia, and polycythemia vera.
  • Iron overload and chronic liver disease increase susceptibility to severe siderophilic infections.

Purpose of the Study:

  • To review preclinical evidence supporting hepcidin agonists as a novel therapeutic class.
  • To explore the potential of hepcidin agonists in managing iron-related disorders and associated infections.

Main Methods:

  • Review of preclinical studies on hepcidin agonist development.
  • Analysis of hepcidin agonist mechanisms in iron regulation and absorption.

Main Results:

  • Hepcidin agonists demonstrate efficacy in regulating blood iron levels.
  • Preclinical data indicate potential for treating iron overload disorders.
  • Evidence suggests a role in preventing complications of siderophilic infections.

Conclusions:

  • Hepcidin agonists represent a promising new therapeutic strategy for iron homeostasis disorders.
  • Further development is warranted to translate preclinical findings into clinical applications for hemochromatosis, beta-thalassemia, and other conditions.